Alnylam Pharmaceuticals, Inc. vs Madrigal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending

Alnylam vs. Madrigal: A Decade of R&D Investment

__timestampAlnylam Pharmaceuticals, Inc.Madrigal Pharmaceuticals, Inc.
Wednesday, January 1, 201419024900068205000
Thursday, January 1, 201527649500054218000
Friday, January 1, 201638239200015934000
Sunday, January 1, 201739063500024390000
Monday, January 1, 201850542000025389000
Tuesday, January 1, 201965511400072324000
Wednesday, January 1, 2020654819000184809000
Friday, January 1, 2021792156000205164000
Saturday, January 1, 2022883015000245441000
Sunday, January 1, 20231004415000271823000
Monday, January 1, 20241126232000
Loading chart...

Igniting the spark of knowledge

Strategic R&D Investments: Alnylam vs. Madrigal

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Alnylam Pharmaceuticals, Inc. and Madrigal Pharmaceuticals, Inc. have demonstrated contrasting strategies in this regard over the past decade. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, reflecting a robust focus on pioneering new treatments. In contrast, Madrigal's R&D spending, while increasing, grew at a more modest pace, approximately 300% during the same period.

Alnylam's aggressive investment strategy is evident, with its R&D expenses peaking at over $1 billion in 2023, a significant leap from $190 million in 2014. Meanwhile, Madrigal's R&D expenses reached $272 million in 2023, up from $68 million in 2014. This divergence highlights Alnylam's strategic emphasis on innovation, potentially positioning it as a leader in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025